Thrivent Financial for Lutherans Reduces Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Thrivent Financial for Lutherans lessened its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 5.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 87,612 shares of the biopharmaceutical company’s stock after selling 5,538 shares during the period. Thrivent Financial for Lutherans owned about 0.07% of Catalyst Pharmaceuticals worth $1,742,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Pacer Advisors Inc. increased its position in shares of Catalyst Pharmaceuticals by 130,918.8% during the second quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company’s stock valued at $45,968,000 after buying an additional 2,965,310 shares during the period. Vanguard Group Inc. boosted its position in Catalyst Pharmaceuticals by 12.1% during the 1st quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock valued at $127,212,000 after acquiring an additional 860,244 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Catalyst Pharmaceuticals by 15.2% during the 2nd quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company’s stock worth $33,702,000 after acquiring an additional 287,300 shares during the period. Integral Health Asset Management LLC bought a new position in shares of Catalyst Pharmaceuticals in the 2nd quarter worth approximately $4,260,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Catalyst Pharmaceuticals by 9.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company’s stock valued at $46,479,000 after purchasing an additional 263,099 shares during the period. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ CPRX opened at $22.07 on Friday. The company has a market cap of $2.63 billion, a PE ratio of 18.70, a P/E/G ratio of 3.44 and a beta of 0.75. The firm’s 50 day moving average price is $21.23 and its 200-day moving average price is $18.72. Catalyst Pharmaceuticals, Inc. has a 52-week low of $13.00 and a 52-week high of $24.27.

Insider Activity at Catalyst Pharmaceuticals

In other news, Director Molly Harper sold 17,500 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total value of $385,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Gary Ingenito sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total transaction of $272,640.00. Following the transaction, the insider now directly owns 51,391 shares of the company’s stock, valued at $1,167,603.52. The trade was a 18.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on CPRX shares. Stephens initiated coverage on Catalyst Pharmaceuticals in a research note on Monday, November 18th. They issued an “overweight” rating and a $35.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Truist Financial upped their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, November 11th. Finally, Citigroup boosted their price target on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Catalyst Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $31.14.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.